SARS-CoV-2 Omicron variant leads to widespread escape from neutralizing antibody responses

By | January 7, 2022
A new study reported the neutralization of Omicron by a large panel of sera collected from convalescent early pandemic, Alpha, Beta, Gamma and Delta infected individuals, as well as among vaccinees receiving three doses of the Oxford/AstraZeneca (AZD1222) or the Pfizer BioNtech (BNT16b2) vaccines.